Somatic mutation-associated T follicular helper cell elevation in lung adenocarcinoma

References

• Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529–542. doi:10.1016/j.immuni.2014.10.004.
   PubMed Web of Science ®Google Scholar
• Shulman Z, Gitlin AD, Targ S, Jankovic M, Pasqual G, Nussenzweig MC, Victora GD. T follicular helper cell dynamics in germinal centers. Science. 2013;341:673–677. doi:10.1126/science.1241680.
   PubMed Web of Science ®Google Scholar
• Victora GD, Schwickert TA, Fooksman DR, Kamphorst AO, Meyer-Hermann M, Dustin ML, Nussenzweig MC. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell. 2010;143:592–605. doi:10.1016/j.cell.2010.10.032.
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571–580. doi:10.1016/j.it.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410–4417. doi:10.1200/JCO.2007.15.0284.
   PubMed Web of Science ®Google Scholar
• Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. 2014;189:832–844. doi:10.1164/rccm.201309-1611OC.
   PubMed Web of Science ®Google Scholar
• Jones GW, Hill DG, Jones SA. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Front Immunol. 2016;7:401. doi:10.3389/fimmu.2016.00401.
   PubMed Web of Science ®Google Scholar
• Schultz BT, Teigler JE, Pissani F, Oster AF, Kranias G, Alter G, Marovich M, Eller MA, Dittmer U, Robb ML, et al. Circulating HIV-specific interleukin-21(+)CD4(+) T cells represent peripheral Tfh cells with antigen-dependent helper functions. Immunity. 2016;44:167–178. doi:10.1016/j.immuni.2015.12.011.
   PubMed Web of Science ®Google Scholar
• Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123:2873–2892. doi:10.1172/JCI67428.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–795. doi:10.1016/j.immuni.2013.10.003.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–2608. doi:10.1158/1535-7163.MCT-17-0386.
   PubMed Web of Science ®Google Scholar
• Becker-Santos DD, Thu KL, English JC, Pikor LA, Martinez VD, Zhang M, Vucic EA, Luk MT, Carraro A, Korbelik J, et al. Developmental transcription factor NFIB is a putative target of oncofetal miRNAs and is associated with tumour aggressiveness in lung adenocarcinoma. J Pathol. 2016;240:161–172. doi:10.1002/path.4765.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–945. doi:10.1038/nm.3909.
   PubMed Web of Science ®Google Scholar
• Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics. 2006;7:123. doi:10.1186/1471-2105-7-123.
   PubMed Web of Science ®Google Scholar
• Pirici D, Mogoanta L, Kumar-Singh S, Pirici I, Margaritescu C, Simionescu C, Stanescu R. Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtype. J Histochem Cytochem. 2009;57:567–575. doi:10.1369/jhc.2009.953240.
   PubMed Web of Science ®Google Scholar
• Robles AI, Arai E, Mathé EA, Okayama H, Schetter AJ, Brown D, Petersen D, Bowman ED, Noro R, Welsh JA, et al. An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thoracic Oncol. 2015;10:1037–1048. doi:10.1097/JTO.0000000000000560.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550. doi:10.1038/nature13385.
   PubMed Web of Science ®Google Scholar
• Conway EM, Pikor LA, Kung SHY, Hamilton MJ, Lam S, Lam WL, Bennewith KL., et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193:116–130. doi:10.1164/rccm.201508-1545CI.
   PubMedGoogle Scholar
• Marshall EA, Ng KW, Kung SHY, Conway EM, Martinez VD, Halvorsen EC, Rowbotham DA, Vucic EA, Plumb AW, Becker-Santos DD, et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer. 2016;15:67. doi:10.1186/s12943-016-0551-1.
   PubMed Web of Science ®Google Scholar
• Xu L, Cao Y, Xie Z, Huang Q, Bai Q, Yang X, He R, Hao Y, Wang H, Zhao T, et al. The transcription factor TCF-1 initiates the differentiation of T(FH) cells during acute viral infection. Nat Immunol. 2015;16:991–999. doi:10.1038/ni.3229.
   PubMed Web of Science ®Google Scholar
• Stone EL, Pepper M, Katayama CD, Kerdiles YM, Lai CY, Emslie E, Lin YC, Yang E, Goldrath AW, Li MO, et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity. 2015;42:239–251. doi:10.1016/j.immuni.2015.01.017.
   PubMed Web of Science ®Google Scholar
• Ise W, Kohyama M, Schraml BU, Zhang T, Schwer B, Basu U, Alt FW, Tang J, Oltz EM, Murphy TL, et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol. 2011;12:536–543. doi:10.1038/ni.2037.
   PubMed Web of Science ®Google Scholar
• Enfield KSS, Kung SHY, Gallagher P, Milne K, Chen Z, Piga D, Lam S, English J, Guillaud M, Macaulay C, et al. P2.01-065 Quantification of tumor-immune cell spatial relationships in the lung tumor microenvironment using single cell profiling. J Thorac Oncol. 2017;12:S826–S827. doi:10.1016/j.jtho.2016.11.1117.
   Web of Science ®Google Scholar
• Alexandrov, LB., Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL,Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi:10.1038/nature12477.
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–546. doi:10.1038/nrc3775.
   PubMed Web of Science ®Google Scholar
• Djureinovic D, Hallström BM, Horie M, Mattsson JSM, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer, et al. Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight. 2016;1:e86837. doi:10.1172/jci.insight.86837.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Pandey A, Saba R, Kim M, Saadeh C, Lukman T, Chiaramonte R, Jenkins M, Cobos E, Jumper C, et al. Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol. 2012;31:321–343. doi:10.3109/08830185.2012.723512.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang B, Liu Z, Jin L, Xing R. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24:978–985. doi:10.1038/s41591-018-0045-3.
   PubMed Web of Science ®Google Scholar
• Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean M-C, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013;19:4079–4091. doi:10.1158/1078-0432.CCR-12-3847.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Cancer: antibodies regulate antitumour immunity. Nature. 2015;521:35–37. doi:10.1038/nature14388.
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den Eynde K, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018. doi:10.1038/s41591-018-0096-5.
   Web of Science ®Google Scholar
• Shinnakasu R, Inoue T, Kometani K, Moriyama S, Adachi Y, Nakayama M, Takahashi Y, Fukuyama H, Okada T, Kurosaki T. Regulated selection of germinal-center cells into the memory B cell compartment. Nat Immunol. 2016;17:861–869. doi:10.1038/ni.3460.
   PubMed Web of Science ®Google Scholar
• Arkatkar T, Du SW, Jacobs HM, Dam EM, Hou B uckner JH, Rawlings DJ, Jackson SW. B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J Exp Med. 2017;214:3207–3217. doi:10.1084/jem.20170580.
   PubMed Web of Science ®Google Scholar
• Qu, Z, Sun F, Zhou J, Li L, Shapiro SD, Xiao G.. Interleukin-6 prevents the initiation but enhances the progression of lung cancer. Cancer Res. 2015;75:3209–3215. doi:10.1158/0008-5472.CAN-14-3042.
   PubMed Web of Science ®Google Scholar
• Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, Daliri S, Chang SH, Ochoa CE, Hanash S, et al. IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-mutant lung cancer. Cancer Res. 2016;76:3189–3199. doi:10.1158/0008-5472.CAN-15-2840.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Lenz H-J, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M, Milano G. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2017;63:48–60. doi:10.1016/j.ctrv.2017.11.008.
   PubMed Web of Science ®Google Scholar